

Individual Treatment Effect Prediction for ALS Patients

Heidi Seibold
Universität Zürich

Achim Zeileis
Universität Innsbruck

Torsten Hothorn
Universität Zürich

Abstract

A treatment for a complicated disease may be helpful for some but not all patients, which makes predicting the treatment effect for new patients important yet challenging. Here we develop a method for predicting the treatment effect based on patient characteristics and use it for predicting the effect of the only drug (Riluzole) approved for treating Amyotrophic Lateral Sclerosis (ALS). Our proposed method of model-based random forests detects similarities in the treatment effect among patients and on this basis computes personalised models for new patients. The entire procedure focuses on a base model, which usually contains the treatment indicator as a single covariate and takes the survival time or a health or treatment success measurement as primary outcome. This base model is used both to grow the model-based trees within the forest, in which the patient characteristics that interact with the treatment are split variables, and to compute the personalised models, in which the similarity measurements enter as weights. We applied the personalised models using data from several clinical trials for ALS from the PRO-ACT database. Our results indicate that some ALS patients benefit more from the drug Riluzole than others. Our method allows shifting from stratified medicine to personalised medicine and can also be used in assessing the treatment effect for other diseases studied in a clinical trial.

Keywords: Personalised medicine, random forest, treatment effect, model-based recursive partitioning.

1. Introduction

Amyotrophic lateral sclerosis (ALS) is a deadly disease that affects motor neurons in the brain and spinal cord, i.e. the neurons responsible for voluntary muscle control. Riluzole (Rilutek) is the only approved drug for this disease to date. According to the [European Medicines Agency \(2012\)](#), Riluzole prolongs the median survival of ALS patients, depending on the dose, by a few months. Several side effects, such as sickness, weakness or increased liver enzyme levels are mentioned ([European Medicines Agency 2012](#)). Knowledge how Riluzole works on the nervous system of ALS patients is limited. The PRO-ACT database ([Atassi *et al.* 2014](#)) is the largest database containing clinical trial data of ALS patients available and was initiated to retrieve more information on the disease. It contains data from 17 ALS studies conducted between 1990 and 2010. Using these data, we aimed at finding out more about the effect of Riluzole on the health and survival of patients.

Before statistical analysis and p -values entered into medical progress, doctors treated patients individually based on their experiences and knowledge ([Weisberg 2015](#)). Since the beginning

of the “golden age of randomised clinical trials”, however, medication became more and more standardised. Nowadays, much knowledge about the effect of drugs has accumulated, cornerstone drugs such as antibiotics have been used for decades and many diseases can be treated successfully; however, providing new drugs for the general public is more difficult. Diseases such as ALS are too complex to treat all patients in the same way. Therefore, there is a need to return to more individualised treatments, but this time with the use of statistical concepts.

In the past years, there has been an immense effort towards personalised medicine in the analysis of randomised controlled trials. The goal is to identify predictive factors, i.e. factors that interact with the treatment (Italiano 2011), such as biomarkers, other treatments, and environmental circumstances. In the following, we will refer to these factors as patient characteristics. Prognostic factors, i.e. factors that directly affect the patient’s outcome, are only of secondary interest, but should not be neglected, because they not only change the general level of the outcome – showing in the individual intercept – but might also be predictive and prognostic (Seibold *et al.* 2015). For drugs for which the biological mode of action is unknown, predictive and prognostic factors should first be identified in a data-driven way. New hypotheses can then be generated and new trials can be planned based on these hypotheses. In this first step we are asking *whether* a certain patient characteristic is relevant and not *why*.

Many new statistical methods in the field of stratified medicine, i.e. subgroup analysis, have been developed. Subgroup analyses aim at finding groups of patients that have differential treatment effects. Most of the methods are based on recursive partitioning (trees) and/or interaction models (Ciampi *et al.* 1995; Kehl and Ulm 2006; Dusseldorp and Van Mechelen 2013; Loh *et al.* 2015; Tian *et al.* 2014; Foster *et al.* 2015; Zhang *et al.* 2012). The tree methods for subgroup analyses have specialised splitting procedures for partitioning the patients into groups with higher and lower treatment effect. Interaction models evaluate the interaction between the treatment and given patient characteristics. The idea behind methods of subgroup analyses in general is to obtain a treatment effect $\beta(\mathbf{z})$ that depends on the patient characteristics \mathbf{z} . For example, the treatment effect could depend on the age of patients, in which patients less than 40 years of age improve through the treatment, patients between 40 and 60 do not improve and patients older than 60 years improve, but less than the patients under 40 years:

$$\beta(\mathbf{z}) = \begin{cases} 1 & \text{if } z_{\text{age}} < 40 \\ 0 & \text{if } 40 \leq z_{\text{age}} < 60 \\ 0.5 & \text{if } 60 \leq z_{\text{age}} \end{cases} \quad (1)$$

However, the assumption that the treatment effect is a step function may be too restrictive, and $\beta(\mathbf{z})$ in reality may be a smooth interaction function. In other words, personalised medicine is required instead of stratified medicine. Because methods for subgroup analyses again generalise the treatment effect for a group of patients, it can only be considered as a step in the direction toward personalised medicine. We provide a method that can estimate smooth treatment effect functions using model-based random forests and weighted models. More importantly, this method provides an estimate for the treatment effect of a future patient, thereby allowing a decision to be made whether treatment of this patient is appropriate.

2. Methods

Seibold *et al.* (2015) introduced a means of conducting subgroup analysis using model-based recursive partitioning. One first defines a model $\mathcal{M}((Y, \mathbf{X}), \boldsymbol{\vartheta})$ with primary endpoint Y , covariates \mathbf{X} including the treatment indicator

$$X_A = \begin{cases} 1 & \text{if patient received the (new) treatment} \\ 0 & \text{if patient received no treatment (or standard of care),} \end{cases} \quad (2)$$

and parameter vector $\boldsymbol{\vartheta}$. In the following we will consider likelihood models (e.g. generalised linear models or parametric survival models) where the model parameters $\boldsymbol{\vartheta}$ can be estimated by maximising the log-likelihood $l((Y, \mathbf{X}), \boldsymbol{\vartheta})$ of those models (e.g. Gaussian log-likelihood or Weibull log-likelihood) or equivalently by solving the score equation

$$\sum_{i=1}^N s((y, \mathbf{x})_i, \boldsymbol{\vartheta}) = \mathbf{0} \quad (3)$$

with

$$s((y, \mathbf{x})_i, \boldsymbol{\vartheta}) = \frac{\partial l((y, \mathbf{x})_i, \boldsymbol{\vartheta})}{\partial \boldsymbol{\vartheta}}. \quad (4)$$

In most applications the model contains only an intercept α and a treatment effect β , i.e. $\mathbf{X} = (1, X_A)$ and $\boldsymbol{\vartheta} = (\alpha, \beta)^\top$ but more parameters are possible, such as coefficients of additional regressors or scale and shape parameters for the response distribution. Technically, there can also be more than two treatment groups. For simplicity, we will focus on the simple case with intercept and treatment effect and two treatment groups. The method obtains subgroups $\{\mathcal{B}_{b=1, \dots, B}\}$ that differ with regard to the treatment effect β and potentially the intercept α . The subgroups are defined by patient characteristics $\mathbf{Z} = (Z_1, \dots, Z_J) \in \mathcal{Z}$. Hence the intercept and treatment parameters can be written as a function of the patient characteristics \mathbf{z} .

Conceptually, the partitioned model parameters $\alpha(\mathbf{z})$ and $\beta(\mathbf{z})$ might depend on \mathbf{z} in a more complex way than a simple tree structure. Therefore, the model parameters are not step functions, but rather smooth interaction functions, so that an individual treatment effect (as in personalised medicine) can be computed for each patient instead of only for each subgroup of patients (as in stratified medicine). The function $\beta(\mathbf{z})$ can then be understood as an estimate of the individual treatment effect of a patient with patient characteristics \mathbf{z} .

The most intuitive step from a tree structure to a more complex structure is to use a random forest instead of a single tree. Hence we propose a model-based random forest for personalised medicine, which can be used to predict the treatment effect of future patients using personalised models.

2.1. Random forest

Random forests (Breiman 2001) compute an ensemble of T trees. The proposed algorithm draws subsamples \mathcal{L}_t , $t = 1, \dots, T$ of the given N observations and fits a model-based tree to each subsample using a randomly sampled set of candidate split variables \mathbf{z} . The data \mathcal{L}_t^c that were not in the learning sample for tree t are called out-of-bag data.

Split procedure

The special feature of our method is the split procedure, which is based on the empirical estimating function

$$\mathbf{s} = \begin{pmatrix} s_{\hat{\alpha}}((y, \mathbf{x})_1, \hat{\boldsymbol{\vartheta}}) & s_{\hat{\beta}}((y, \mathbf{x})_1, \hat{\boldsymbol{\vartheta}}) \\ s_{\hat{\alpha}}((y, \mathbf{x})_2, \hat{\boldsymbol{\vartheta}}) & s_{\hat{\beta}}((y, \mathbf{x})_2, \hat{\boldsymbol{\vartheta}}) \\ \vdots & \vdots \\ s_{\hat{\alpha}}((y, \mathbf{x})_N, \hat{\boldsymbol{\vartheta}}) & s_{\hat{\beta}}((y, \mathbf{x})_N, \hat{\boldsymbol{\vartheta}}) \end{pmatrix} \quad (5)$$

which contains the score contributions $s_{\hat{\alpha}}((y, \mathbf{x})_i, \hat{\boldsymbol{\vartheta}})$ and $s_{\hat{\beta}}((y, \mathbf{x})_i, \hat{\boldsymbol{\vartheta}})$. The score contributions are the partial derivatives of the log-likelihood with respect to α or β respectively evaluated at the N observed data points and the estimated parameters $\hat{\boldsymbol{\vartheta}} = (\hat{\alpha}, \hat{\beta})^\top$ (Zeileis *et al.* 2008). The matrix of score contributions contains information on the deviation from the model fit for all parameters and observations of a given model $\mathcal{M}((Y, \mathbf{X}), \boldsymbol{\vartheta})$. The contributions can thus be seen as residuals.

To obtain a split in model-based recursive partitioning for this setup the following steps have to be performed:

- Compute the prespecified (parametric) model $\mathcal{M}((Y, \mathbf{X}), \boldsymbol{\vartheta})$.
- Compute the associated score matrix \mathbf{s} .
- Perform tests of independence between the residuals (partial score vectors) and the partitioning variables:

$$\begin{aligned} H_0^{\alpha,j} &: s_{\hat{\alpha}}((Y, \mathbf{X}), \hat{\boldsymbol{\vartheta}}) \perp Z_j \\ H_0^{\beta,j} &: s_{\hat{\beta}}((Y, \mathbf{X}), \hat{\boldsymbol{\vartheta}}) \perp Z_j \quad j = 1, \dots, J \end{aligned}$$

The smallest p -value corresponds to the greatest deviation from the model assumption, that intercept and treatment parameter are the same for all patients in the given node/subgroup.

- If any p -value is lower than the significance level, select the partitioning variable that has the highest association (lowest p -value) to any of the relevant residuals for the split.
- Search for the optimal split point in the selected partitioning variable using a suitable criterion, such that the models in the resulting daughter-nodes have as little association between the partitioning variable and the residuals as possible.

This split procedure is repeated until a stop criterion is met. This can be, for example, when no p -values are lower than the significance level or if subgroups become too small. In the end a tree is obtained with disjoint subgroups

$$\dot{\bigcup}_b \mathcal{B}_b = \mathcal{Z} \quad (6)$$

or a random forest with T trees and disjoint subgroups for each tree

$$\dot{\bigcup}_b \mathcal{B}_{tb} = \mathcal{Z} \quad \forall t = 1, \dots, T. \quad (7)$$

The independence tests can be performed using permutation tests (Hothorn *et al.* 2006a,b) or, for reasonably large samples, using M-fluctuation tests (Zeileis and Hornik 2007; Zeileis *et al.* 2008). Note that multiplicity adjustment, e.g. Bonferroni correction, is recommended. More details on the algorithm and the test procedures used are documented in the appendix.

2.2. Personalised models

In personalised medicine, the goal is to learn how much a person will profit from a given treatment and what would happen if the standard of care or no treatment is given. For any patient, it is possible to compute a personalised model based on the similarity of this observation to the observations in the training data. The similarity $w_i(\mathbf{z})$ of a patient i to any patient from the training set is given as the number of times the patients are classified in the same subgroup by the single trees in the random forest

$$w_i(\mathbf{z}) = \sum_{t=1}^T \sum_{b=1}^{B_t} (\mathbf{z}_i \in \mathcal{B}_{tb}) \wedge (\mathbf{z} \in \mathcal{B}_{tb}), \quad (8)$$

with T being the number of trees used for the computation of the forest and B_t being the number of subgroups from tree t (Hothorn *et al.* 2004; Meinshausen 2006). If patient i is part of the training set, the weights can be computed out-of-bag, i.e. the only trees ($t = 1, \dots, T$) considered are those where patient i is not in the subset \mathcal{L}_t for the computation.

To obtain the personalised model for patient i the base model is recomputed with the weighted training data or equivalently by using the weighted score function in the score equation

$$\sum_{k=1}^N w_i(\mathbf{z}_k) \cdot s((y, \mathbf{x})_i, \boldsymbol{\vartheta}(\mathbf{z}_i)) = 0. \quad (9)$$

In other words every patient k from the training set is included $w_i(\mathbf{z}_k)$ times in the “new data set” to compute the personalised model for patient i . In the following the parameters estimated from this model will be denoted by $\hat{\boldsymbol{\vartheta}}(\mathbf{z}_i) = (\hat{\alpha}(\mathbf{z}_i), \hat{\beta}(\mathbf{z}_i), \dots)$.

Using the personalised models it is possible to obtain a log-likelihood. From the personalised model for patient i , the log-likelihood contribution $l((y, \mathbf{x})_i, \hat{\boldsymbol{\vartheta}}(\mathbf{z}_i))$ for this observation is computed. The log-likelihood then is

$$\sum_{i=1}^N l\left((y, \mathbf{x})_i, \hat{\boldsymbol{\vartheta}}(\mathbf{z}_i)\right), \quad (10)$$

which we refer to as forest log-likelihood.

2.3. Improvement through personalised models

To check whether the personalised models actually lead to an improvement of the base model

we test the hypothesis

$$H_0 : \underbrace{\alpha(\mathbf{Z}) \equiv \alpha}_{H_0^\alpha} \tag{11}$$

$$\bigcap \underbrace{\beta(\mathbf{Z}) \equiv \beta}_{H_0^\beta}. \tag{12}$$

This strict null hypothesis is to be rejected, if any of the patient characteristics contain information on the outcome or the treatment effect. To conduct the test, one can proceed as follows:

- Compute the forest log-likelihood and the log-likelihood of the base model and calculate their difference.
- Draw parametric bootstrap samples from the base model.
- Compute the forest log-likelihood and the log-likelihood of the base model in the bootstrap samples and again compute the differences.
- The p -value is then the proportion of bootstrap samples in which the difference in log-likelihoods exceeds the observed difference in the original data. Note, that this p -value will be very low or even zero when the patient characteristics contain information on the outcome or the treatment effect.

In practice, one may be interested in just H_0^β , but testing the sub-hypotheses H_0^α and H_0^β separately is not straight forward. An approximation would be to compute the personalised models using a forest that splits only based on the partial score function with respect to α or β respectively. Patient characteristics, however, are often not exclusively predictive or prognostic but may be both. Also, if a patient characteristic is purely prognostic, this still may result in a pattern in both partial score functions. For more details, see [Seibold *et al.* \(2015\)](#).

2.4. Dependence plots

A partial dependence plot describes the dependence of a function (in our case the treatment effect $\hat{\beta}(\mathbf{z})$) and a variable (in our case a partitioning variable) ([Hastie *et al.* 2009](#)). The partial dependence plot resulting from a model-based tree would show a step function. The partial dependence from a random forest can be smoother for continuous partitioning variables. It can be obtained by plotting $\hat{\beta}(z_j)$ against z_j for each partitioning variable $j = 1, \dots, J$.

2.5. Variable importance

The variable importance for the random forest is computed based on the tree log-likelihoods. For a given forest computed with T trees the log-likelihood is computed as follows:

- Select the out-of-bag data \mathcal{L}_i^c and determine the terminal node/subgroup to which each observation i belongs to.

- Compute the log-likelihood contribution of each observation $i \in \mathcal{L}_t^c$ based on the respective model in the terminal node/subgroup with parameters $\hat{\boldsymbol{\vartheta}}(\mathbf{z}_i)$.
- Compute the out-of-bag log-likelihood as the sum of the contributions

$$l_t = \sum_{i \in \mathcal{L}_t^c} l((y, \mathbf{x})_i, \hat{\boldsymbol{\vartheta}}(\mathbf{z}_i)). \quad (13)$$

To obtain the variable importance of a given variable z_j , $j = 1, \dots, J$, the variable is permuted. The log-likelihood is computed as above, except that the column with information about z_j in the out-of-bag data is replaced by the permuted z_j . We denote the log-likelihood of tree t with variable z_j permuted by $l_t^{(j)}$. The variable importance is then

$$\text{VI}_j = \frac{1}{T} \sum_{t=1}^T [l_t - l_t^{(j)}]. \quad (14)$$

If the variable importance is high the variable is an important predictive and/or prognostic factor. Note that due to the absolute differences the variable importances may be negative.

3. Results

3.1. PRO-ACT data

The Pooled Open Access Clinical Trials (PRO-ACT, <https://nctu.partners.org/ProACT>) database contains longitudinal data of ALS patients that participated in one of 16 phase II and III trials and one observational study. It is a project initiated by the non-profit organisation Prize4Life (<http://www.prize4life.org/>) to enhance knowledge about ALS. It contains information on a broad variety of patient characteristics, such as vital signs, the patient's and family's history, and treatment information. Identification criteria, such as study centres, are not included in the database. Also collected are the survival time and the ALS functional rating scale (ALSFRS), which is a score measuring the patients ability of living a normal life (Brooks *et al.* 1996). The ALSFRS is a sum-score of ten items, each of which ranges between zero and four, where zero represents complete inability and four represents normal ability. The items are speech, salivation, swallowing, hand-writing, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, and breathing. As outcomes in the study we used both the survival time (denoted by survival) and the ALSFRS six months after treatment start (denoted by ALSFRS₆) and identified patient characteristics that influence the effect of Riluzole on these outcomes. For the two outcome variables, we obtained two different data sets. We only included observations that contain information on the respective outcome variable and only patient characteristics that have fewer than 50% missing values. The survival time data set contains 3306 observations and 18 patient characteristics. The ALSFRS data set contains 2534 observations and 57 patient characteristics.

Tables 1 and 2 show the estimates including standard errors obtained from the base model for each outcome. For the ALSFRS this base model is given by

$$\mathbb{E} \left(\frac{\text{ALSFRS}_6}{\text{ALSFRS}_0} \middle| X = x \right) = \frac{\mathbb{E}(\text{ALSFRS}_6 | X = x)}{\text{ALSFRS}_0} = \exp\{\alpha + \beta x_A\}, \quad (15)$$

Table 1: ALSFRS base model (Gaussian generalised linear model with log-link and offset). Given are the parameter estimates, their standard error and the Wald confidence interval.

	Estimate	Std.Error	2.5 %	97.5 %
α	-0.1595	0.0065	-0.1722	-0.1468
β	0.0091	0.0077	-0.0060	0.0242

Table 2: Survival time base model (Weibull model). Given are the parameter estimates, their standard error and the Wald confidence interval.

	Estimate	Std.Error	2.5 %	97.5 %
α_1	6.7070	0.0323	6.6437	6.7703
β	0.1073	0.0387	0.0314	0.1832
$\log(\alpha_2)$	-0.5833	0.0271	-0.6364	-0.5302

which represents a Gaussian generalised linear model with log-link and offset $\log(\text{ALSFRS}_0)$ where ALSFRS_0 is the ALSFRS that was measured at the time of treatment start. The base model for the survival time is given by the Weibull model

$$\mathbb{P}(T \leq \text{survival} | X = x) = F\left(\frac{\log(\text{survival}) - \alpha_1 - \beta x_A}{\alpha_2}\right), \quad (16)$$

where F is the cumulative distribution function of the Gompertz distribution. Note that the Weibull model has a scale parameter in addition to the intercept, so that both α_1 and α_2 control the appearance of the baseline hazard. In the notation of Equation 4, this leads to $\vartheta = (\alpha_1, \alpha_2, \beta)^\top$.

3.2. Personalised models

We computed personalised models for all observations in the respective training data, which were used to obtain the random forest. The distribution of parameter estimates in the personalised models is given in Figure 1 for the ALSFRS and in Figure 2 for the survival time. Figure 1 shows that all patients are predicted to have a positive Riluzole effect, i.e. for all patients taking Riluzole, a higher ALSFRS is achieved compared to those not taking Riluzole. However, there is a variability in the treatment effects, and the distribution of the treatment effect is bimodal (as is the distribution of the intercept). The treatment effect estimated from the base model is between the two modes. The lowest treatment effect a person in this data set is predicted to have is 0.0027.

For the survival time, the lowest predicted treatment effect is 0.0717. However, the value of the treatment effect in the personalised survival models cannot be interpreted in isolation; its meaning depends on the shape of the baseline hazard, i.e. on α_1 and α_2 . Instead of depicting the densities of the two baseline hazard parameters, in Figure 2 we show the baseline hazard curves. The baseline hazard varies for different patients and there is a gap in the middle. The baseline hazard estimated from the base model lies close to that gap.




Figure 1: Kernel density estimates of the personalised parameter estimates for the ALSFRS.




Figure 2: Distribution of the personalised parameter estimates for the survival time. The baseline hazard functions are given in the left panel; the kernel density estimate of the treatment effect estimate are given in the right panel.




Figure 3: Difference in log-likelihoods between forest and base model on the original data (dashed lines; H_1 , the usual forest; H_1^α the forest that splits based on α ; H_1^β the forest that splits based on β) and on 50 samples simulated from the base model (density curve) for the ALSFRS outcome.

From the personalised models, we obtained the “forest log-likelihoods” for both outcomes. For the Gaussian GLM with log-link and offset, the log-likelihood contribution for observation i is defined as

$$\begin{aligned} l\left(\left(\text{ALSFRS}_6, \text{ALSFRS}_0, \mathbf{x}\right)_i, \hat{\boldsymbol{\vartheta}}(\mathbf{z}_i)\right) \\ = \left(\text{ALSFRS}_{6i} - \exp\left(\mathbf{x}_i^\top \hat{\boldsymbol{\vartheta}}(\mathbf{z}_i)\right) \cdot \text{ALSFRS}_{0i}\right)^2 \end{aligned} \quad (17)$$

with $\mathbf{x}_i = (1, x_{Ai})^\top$ and $\hat{\boldsymbol{\vartheta}}(\mathbf{z}_i) = (\hat{\alpha}(\mathbf{z}_i), \hat{\beta}(\mathbf{z}_i))^\top$. For the Weibull model the log-likelihood contribution for observation i is

$$\begin{aligned} l\left(\left(\text{survival}, \mathbf{x}\right)_i, \hat{\boldsymbol{\vartheta}}(\mathbf{z}_i)\right) \\ = \delta_i \log(\hat{\alpha}_2(\mathbf{z}_i)) - \delta_i \frac{\text{survival}_i - \mathbf{x}_i^\top \hat{\boldsymbol{\vartheta}}^*(\mathbf{z}_i)}{\hat{\alpha}_2(\mathbf{z}_i)} + \exp\left(\frac{\text{survival}_i - \mathbf{x}_i^\top \hat{\boldsymbol{\vartheta}}^*(\mathbf{z}_i)}{\hat{\alpha}_2(\mathbf{z}_i)}\right) \end{aligned} \quad (18)$$

with $\mathbf{x}_i = (1, x_{iA})^\top$, $\hat{\boldsymbol{\vartheta}}^*(\mathbf{z}_i) = (\hat{\alpha}_1(\mathbf{z}_i), \hat{\beta}(\mathbf{z}_i))^\top$ and δ_i as the censoring indicator.

As can be seen in Figures 3 and 4 the forest log-likelihoods are higher than the log-likelihoods of the base models for both the ALSFRS and the survival time. The figures show the difference in log-likelihood between the forest and the corresponding base model. To show that this difference is not due to overfitting, we drew 50 samples from the base models, i.e. 50 parametric bootstrap samples for which the assumption holds that the intercept (or baseline hazard) and treatment effect are the same for all patients. ALSFRS values are drawn from a normal distribution truncated at zero to assure positivity. (The effect of truncation is virtually negligible; only two observations had a truncation probability of more than 1%.) The survival times are drawn from a Weibull distribution censored at the originally observed censoring





Figure 4: Difference in log-likelihoods between forest and base model on the original data (dashed lines; H_1 , the usual forest; H_1^α the forest that splits based on α ; H_1^β the forest that splits based on β) and on 50 samples simulated from the base model (density curve) for the survival outcome.


times (if exceeded). The difference in log-likelihoods for both ALSFRS and survival time are distributed close to zero, with a slight shift to the right, for the parametric bootstrap samples. The large difference in the ALS data supports the assumption that the base models are not ideal and personalised models are meaningful (the respective p-values are both zero). To approximately check the sub-hypotheses given in equation 11 and 12, we also computed log-likelihoods of the two forests that split only with respect to one of the partial score functions – either intercept (or baseline hazard) or treatment effect. For the ALSFRS, both the forest under H_1^α (computed with only splitting based on the partial score function with respect to the intercept α), as well as the forest under H_1^β (computed with only splitting based on partial score function with respect to the treatment effect β), greatly improved compared to the base model. The difference in log-likelihood between the forest under H_1^α and the base model is even greater than between the original forest (H_1) and the base model. For the survival time, the log-likelihoods of the original forest and the forest under H_1^α (based on splits in the partial score function with respect to the baseline hazard) are very close to each other. Splitting only based on the partial score function with respect to the treatment effect (H_1^β) already improves the log-likelihood but not as much as splitting based on both intercept and treatment effect (H_1). The good performance of the forests under H_1^α indicate that (1) there are no predictive patient characteristics, (2) all predictive patient characteristics are also prognostic, or (3) the predictive nature of the predictive patient characteristics are so strong that it has enough impact on the structure of the partial score function with respect to α .

3.3. Dependence plots


The dependence plots as shown in Figures 5 and 6 can be obtained for any partitioning variable. Here we show the dependence plots for the four variables with the highest variable




(a) Dependence plot for the time in days between disease onset and treatment start.



(b) Dependence plot for the creatinine level in mmol/L.




(c) Dependence plot for the phosphorus level in mmol/L.




(d) Dependence plot for the forced vital capacity (volume of air in litres that can forcibly be blown out after full inspiration).


Figure 5: Dependence plots for the four patient characteristics with the highest variable importance from the ALSFRS forest.




(a) Dependence plot for the age.



(b) Dependence plot for the time in days between disease onset and treatment start.



(c) Dependence plot for the weakness indicator.



(d) Dependence plot for the height.

Figure 6: Dependence plots for the four patient characteristics with the highest variable importance from the survival time forest.

importance (see Section 3.4). For continuous variables, such as age, we show a scatter plot, as before. For categorical variables, such as the variable weakness, which indicates whether a patient suffers from muscle weakness (yes/no), boxplots giving the variation of $\beta(z)$ and a square representing $\bar{\beta}(z)$, i.e. the mean, are a meaningful way of representing the dependence between treatment effect and the given variable.

The most obvious pattern of the four graphs in Figure 5 is shown in Subfigure 5d, in which the personalised treatment effects are plotted against the forced vital capacity (FVC). Patients with a low lung function (low FVC) are predicted to have a higher treatment effect than those with better lung function. The graph shows a relatively clear cut at approximately three litres. This indicates that FVC is a predictive factor. For the time between disease onset and treatment start, the pattern is less clear. Patients with a short as well as those with a long time between disease onset and treatment start seem to benefit most. Also for the creatinine value, which indicates kidney function, only weak patterns are observed. The phosphorus balance is slightly negatively associated with the treatment effect.

For the survival time, plotting only the treatment effect against a variable is not meaningful since the interpretation of the treatment effect depends on the shape of the baseline hazard. Therefore, we took a different approach in this case and show on the y -axis the difference in median survival between treatment and control intake. For example, a value of 70 means that based on the personalised model of this patient, the median survival is prolonged by 70 days if the patient takes Riluzole. The difference in median survival is denoted by $\Delta_{0.5}$. Any other quantile could be used as well since from the Weibull model, information on the entire estimated distribution in the two treatment groups is obtained. Taking the difference in medians makes sense because it is a measure on the scale of the outcome, just as the treatment effect in a linear model, which is the difference in means. The shape of $\Delta_{0.5}$ when plotted against age shows a strong pattern that indicates that age is a predictive factor (see Figure 6). The treatment efficacy increases with age until about 55 years and then flattens. The difference in median survival slightly increases with the days between disease onset and start of treatment in the beginning, but decreases again after about 1000 days. Patients who suffer from weakness have a greater variance in their benefit from Riluzole. Tall patients are predicted to benefit little on average.

3.4. Variable importance

Figures 7 and 8 show the variable importance of each split variable. Figure 7 suggests that the time between disease onset and start of treatment plays the most important role for the personalised models. The time between disease onset and start of treatment, the forced vital capacity (FVC), and the phosphorus balance have been shown to be the most important variables for stratified models (Seibold *et al.* 2015) which is underlined by this analysis. The time between disease onset and start of treatment contains information on the state of disease progression for patients in the trial. If the disease onset and the start of treatment are far apart, the patient is likely to have a slow progression (Hothorn and Jung 2014). Also Riluzole has been shown to not be effective when the disease is already far progressed (European Medicines Agency 2012). Thus it is not surprising that this variable is selected as an important variable.

For the Riluzole effect on the survival time the patient's age and again the time between onset and treatment start play a role. Both variables have been identified before (Seibold




Figure 7: Variable importances of all split variables used for the ALSFRS forest.




Figure 8: Variable importances of all split variables used for the survival time forest.

et al. 2015) as important factors for survival time.

4. Discussion

Model-based forests can find important predictive and prognostic patient characteristics and – more importantly – via the personalised models provide the possibility to predict the treatment effect of a future patient. Through analysis of the PRO-ACT data and simulations (see appendix B), we showed that personalised models can perform better than the standard global model if there are differences in treatment effect between patients. If there is no difference, the performance of the methods is about the same. These results allow a shift from standardised medicine back to personalised medicine, but this time in a controlled way by using statistical principles.

The presented methods are based on tree-based subgroup analyses but go a step further. Not only are subgroups identified and the treatment effect within each group estimated, but many slightly varying trees are used to retrieve a measure of similarity between patients. On this basis, a model is computed in which more similar patients are weighted higher. The personalised models provide point estimates for the treatment effect. When the individual treatment effects are plotted against patient characteristics researchers can determine on whether the patient characteristics are predictive factors and in what way the patient characteristics and the treatment effect are interacting. For ALS patients, the FVC value was predictive on the ALSFRS, and the patient’s age and height were predictive on survival. The next step would be to generate hypotheses from these findings and plan a study to test these. Our method offers a promising means of providing individual treatment effect predictions and can be applied to any clinical trial data where baseline patient characteristics are available.

All results were obtained solely using open-source implementation software (see Section 5), which provides easy access to the methods.

5. Computational details

The code for data preprocessing of the PRO-ACT data is available in the TH.data package (Hothorn 2014). The source code for the full analyses is available on https://github.com/HeidiSeibold/personalised_medicine. Implementation of all methods discussed in this paper are based on the R partykit package (Hothorn and Zeileis 2015, version 1.0-2). Other R packages used were sandwich (Zeileis 2004, 2006, 2.3-3), survival (Therneau 2015, 2.38-1), eha (Broström 2014, 2.4-2) and ggplot2 (Wickham 2009, 2.0.0). All computations were conducted in the R system for statistical computing (R Core Team 2016, version 3.2.0).

Acknowledgements

We thank the Swiss National Fund for funding this project with grant 205321_163456.

References

Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I,

- Schoenfeld D, Cudkowicz M, Leitner M (2014). “The PRO-ACT Database: Design, Initial Analyses, and Predictive Features.” *Neurology*, **83**(19), 1719–1725. doi:10.1212/WNL.0000000000000951.
- Breiman L (2001). “Random Forests.” *Machine Learning*, **45**(1), 5–32. doi:10.1023/A:1010933404324.
- Brooks BR, Sanjak M, Ringel S, England J, Brinkmann J, Pestronk A, Florence J, Mitsumoto H, Szirony K, Wittes J, Charatan M, Stambler N, Cedarbaum JM (1996). “The Amyotrophic Lateral Sclerosis Functional Rating Scale – Assessment of Activities of Daily Living in Patients with Amyotrophic Lateral Sclerosis.” *Archives of Neurology*, **53**(2), 141–147.
- Broström G (2014). *eha: Event History Analysis*. R package version 2.4-2, URL <http://CRAN.R-project.org/package=eha>.
- Ciampi A, Negassa A, Lou Z (1995). “Tree-Structured Prediction for Censored Survival-Data and the Cox Model.” *Journal of Clinical Epidemiology*, **48**(5), 675–689. doi:10.1016/0895-4356(94)00164-L.
- Dusseldorp E, Van Mechelen I (2013). “Qualitative Interaction Trees: A Tool to Identify Qualitative Treatment-Subgroup Interactions.” *Statistics in Medicine*, **33**(2), 219–237. doi:10.1002/sim.5933.
- European Medicines Agency (2012). “Riluzole Zentiva: EPAR Summary for the Public.” URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002622/WC500127609.pdf.
- Foster JC, Taylor JMG, Kaciroti N, Nan B (2015). “Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.” *Biostatistics*, **16**(2), 368–382. doi:10.1093/biostatistics/kxu049.
- Hastie T, Tibshirani R, Friedman J (2009). *The Elements of Statistical Learning*. Springer Series in Statistics. Springer, 2nd edition.
- Hothorn T (2014). *TH.data: TH’s Data Archive*. R package version 1.0-4, URL <http://CRAN.R-project.org/package=TH.data>.
- Hothorn T, Hornik K, Van de Wiel MA, Zeileis A (2006a). “A Lego System for Conditional Inference.” *The American Statistician*, **60**(3), 257–263. doi:10.1198/000313006X118430.
- Hothorn T, Hornik K, Zeileis A (2006b). “Unbiased Recursive Partitioning: A Conditional Inference Framework.” *Journal of Computational and Graphical Statistics*, **15**(3), 651–674. doi:10.1198/106186006X133933.
- Hothorn T, Jung HH (2014). “RandomForest4Life: A Random Forest for Predicting ALS Disease Progression.” *Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration*, **15**(5-6), 444–452. doi:10.3109/21678421.2014.893361.
- Hothorn T, Lausen B, Benner A, Radespiel-Tröger M (2004). “Bagging Survival Trees.” *Statistics in Medicine*, **23**(1), 77–91. doi:10.1002/sim.1593.

- Hothorn T, Zeileis A (2015). “partykit: A Modular Toolkit for Recursive Partytioning in R.” *Journal of Machine Learning Research*, **16**, 3905–3909. URL <http://jmlr.org/papers/v16/hothorn15a.html>.
- Italiano A (2011). “Prognostic or Predictive? It’s Time to Get Back to Definitions!” *Journal of Clinical Oncology*, **29**(35), 4718–4718. doi:10.1200/JCO.2011.38.3729.
- Kehl V, Ulm K (2006). “Responder Identification in Clinical Trials with Censored Data.” *Computational Statistics & Data Analysis*, **50**(5), 1338–1355. doi:10.1016/j.csda.2004.11.015.
- Loh WY, He X, Man M (2015). “A Regression Tree Approach to Identifying Subgroups with Differential Treatment Effects.” *Statistics in Medicine*. doi:10.1002/sim.6454.
- Meinshausen N (2006). “Quantile Regression Forests.” *Journal of Machine Learning Research*, **7**, 983–999. URL <http://www.jmlr.org/papers/v7/meinshausen06a.html>.
- R Core Team (2016). *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- Seibold H, Zeileis A, Hothorn T (2015). “Model-based Recursive Partitioning for Subgroup Analyses.” *International Journal of Biostatistics*. doi:10.1515/ijb-2015-0032. Accepted 2015-10-02.
- Strasser H, Weber C (1999). “On the Asymptotic Theory of Permutation Statistics.” *Mathematical Methods of Statistics*, **8**, 220–250. URL <http://epub.wu.ac.at/102/1/document.pdf>.
- Therneau TM (2015). *A Package for Survival Analysis in S*. Version 2.38, URL <http://CRAN.R-project.org/package=survival>.
- Tian L, Alizadeh AA, Gentles AJ, Tibshirani R (2014). “A Simple Method for Estimating Interactions Between a Treatment and a Large Number of Covariates.” *Journal of the American Statistical Association*, **109**(508), 1517–1532. doi:10.1080/01621459.2014.951443.
- Weisberg HI (2015). “What next for randomised clinical trials?” *Significance*, **12**(1), 22–27. doi:10.1111/j.1740-9713.2015.00798.x.
- Wickham H (2009). *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York. ISBN 978-0-387-98140-6. URL <http://had.co.nz/ggplot2/book>.
- Zeileis A (2004). “Econometric Computing with HC and HAC Covariance Matrix Estimators.” *Journal of Statistical Software*, **11**(10), 1–17. doi:10.18637/jss.v011.i10.
- Zeileis A (2006). “Object-Oriented Computation of Sandwich Estimators.” *Journal of Statistical Software*, **16**(9), 1–16. doi:10.18637/jss.v016.i09.
- Zeileis A, Hornik K (2007). “Generalized M-fluctuation Tests for Parameter Instability.” *Statistica Neerlandica*, **61**(4), 488–508. doi:10.1111/j.1467-9574.2007.00371.x.
- Zeileis A, Hothorn T, Hornik K (2008). “Model-Based Recursive Partitioning.” *Journal of Computational and Graphical Statistics*, **17**(2), 492–514. doi:10.1198/106186008X319331.

Zhang B, Tsiatis AA, Laber EB, Davidian M (2012). “A Robust Method for Estimating Optimal Treatment Regimes.” *Biometrics*, **68**(4), 1010–1018. doi:[10.1111/j.1541-0420.2012.01763.x](https://doi.org/10.1111/j.1541-0420.2012.01763.x).

A. Split algorithm in detail

In the following, the split algorithm in model-based recursive partitioning is explained. The split procedure starts with all N data points. In nodes other than the root node, the size of the data set depends on the previous splits. For notational simplicity, we describe the split procedure in the root node, i.e. for patients $i = 1, \dots, N$.

- Compute prespecified (parametric) model $\mathcal{M}((Y, \mathbf{X}), \boldsymbol{\vartheta})$. Estimate $\hat{\boldsymbol{\vartheta}}$ by maximising the log-likelihood

$$\hat{\boldsymbol{\vartheta}} = \underset{\boldsymbol{\vartheta}}{\operatorname{argmax}} l((Y, \mathbf{X}), \boldsymbol{\vartheta})$$

or equivalently by solving

$$\sum_{i=1}^N s((y, \mathbf{x})_i, \boldsymbol{\vartheta}) = 0$$

for $\boldsymbol{\vartheta}$.

- Compute associated empirical estimating function (residuals)

$$\mathbf{s} = \begin{pmatrix} s_{\hat{\alpha}}((y, \mathbf{x})_1, \hat{\boldsymbol{\vartheta}}) & s_{\hat{\beta}}((y, \mathbf{x})_1, \hat{\boldsymbol{\vartheta}}) \\ s_{\hat{\alpha}}((y, \mathbf{x})_2, \hat{\boldsymbol{\vartheta}}) & s_{\hat{\beta}}((y, \mathbf{x})_2, \hat{\boldsymbol{\vartheta}}) \\ \vdots & \vdots \\ s_{\hat{\alpha}}((y, \mathbf{x})_N, \hat{\boldsymbol{\vartheta}}) & s_{\hat{\beta}}((y, \mathbf{x})_N, \hat{\boldsymbol{\vartheta}}) \end{pmatrix}$$

- Perform tests of independence between residuals (partial score vectors) $\mathbf{s}_{\hat{\alpha}}$ as well as $\mathbf{s}_{\hat{\beta}}$ and partitioning variables Z_j .

$$\begin{aligned} H_0^{\alpha,j} : \quad & \mathbf{s}_{\hat{\alpha}}((Y, \mathbf{X}), \hat{\boldsymbol{\vartheta}}) \perp Z_j \\ H_0^{\beta,j} : \quad & \mathbf{s}_{\hat{\beta}}((Y, \mathbf{X}), \hat{\boldsymbol{\vartheta}}) \perp Z_j \quad j = 1, \dots, J \end{aligned}$$

For the tests, we use permutation testing with the linear statistic

$$T_j = \sum_{i \in \mathcal{B}_b} g_j(Z_{ji}) \cdot \mathbf{s}_i$$

The transformation function g depends on the scale of the variable Z_j . If Z_j is numeric then $g_j(z_{ji}) = z_{ji}$. If Z_j is categorical with K categories then $g_j(z_{ji}) = e_K(z_{ji}) = (I(z_{ji} = 1), \dots, I(z_{ji} = K))$, i.e., g_j is the unit vector of length K , where the element, that corresponds to the value of z_{ji} , is one. If there are missing values in Z_j the observations are excluded from the sum so that we actually sum over all observations $i \in \mathcal{B}_b$, except for the observations in \mathcal{B}_b , where Z_j is missing. The standardised test statistic is the Pearson correlation coefficient

$$c(t_j, \mu_j, \Sigma_j) = \left| \frac{(t_j - \mu_j)}{\sqrt{(\Sigma_j)}} \right|$$

if Z_j is numeric and otherwise

$$c(\mathbf{t}_j, \mu_j, \Sigma_j) = \max_{k=1, \dots, K} \left| \frac{(\mathbf{t}_j - \mu_j)_k}{\sqrt{(\Sigma_j)_{kk}}} \right|.$$

The conditional expectation μ_j and covariance Σ_j can be derived as in [Strasser and Weber \(1999\)](#). The smallest p -value corresponds to the largest discrepancy from the model assumption, that intercept and treatment parameter are the same for all patients in the given node/subgroup.

- If any Bonferroni adjusted p -value is lower than the significance level, select the partitioning variable Z_{j^*} that has the highest association (lowest p -value) to any of the residuals relevant for the split.
- Select as split point the point that results in the largest discrepancy between score functions in the two resulting subgroups. The discrepancy can be measured by the linear statistic

$$T_{j^*}^k = \sum_{i \in \mathcal{B}_{1k}} \mathbf{s}_i,$$

where \mathcal{B}_{1k} here is the first of the two new subgroups that are defined by splitting in split point k of variable Z_{j^*} . The split point is then chosen as follows:

$$k^* = \underset{k}{\operatorname{argmin}} c(t_{j^*}^k, \mu_{j^*}^k, \Sigma_{j^*}^k).$$

B. Empirical evaluation

To check whether the proposed method can recover smooth treatment effect functions, we evaluated its performance on artificial data. To do so, we simulated data from a normal linear regression model. We simulated ten correlated patient characteristics, where only one is in a non-linear interaction with the treatment. In the following, we compare the log-likelihood of our method to the log-likelihood of the true underlying model and the naive model that assumes an overall applicable treatment effect ([Section B.1](#)) and show the predicted treatment effects in dependence plots ([Section B.2](#)) and the variable importances of the true predictive factor and the noise variables ([Section B.3](#)).

We simulated 600 patients, half of which were treated ($x_A = 1$) and half of which were untreated ($x_A = 0$). The ten partitioning variables \mathbf{Z} are normally distributed

$$\mathbf{Z} \sim \mathcal{N}_{10}(\mathbf{0}, \Sigma_Z) \tag{19}$$

and correlated with the covariance matrix

$$\Sigma_Z = \begin{pmatrix} 1 & 0.2 & \cdots & 0.2 \\ 0.2 & 1 & \cdots & 0.2 \\ \vdots & \vdots & \ddots & \vdots \\ 0.2 & 0.2 & \cdots & 1 \end{pmatrix}.$$

The primary outcome depends on treatment and partitioning variables as follows

$$Y | \mathbf{X} = \mathbf{x}, \mathbf{Z} = \mathbf{z} \sim \mathcal{N}(1.9 + 0.2 \cdot x_A + 3 \cdot \cos(z_1) \cdot x_A, 1). \tag{20}$$




Figure 9: True treatment effect in given simulated data.

In this example the true model parameters are defined as follows:

$$\begin{aligned}\alpha(\mathbf{z}) &= 1.9 \\ \beta(\mathbf{z}) &= 0.2 + 0.3 \cdot \cos(z_1).\end{aligned}\tag{21}$$

This means that the treatment effect depends on the value of z_1 and this dependency has the form of a cosine function (see Figure 9).

B.1. Comparison of models by comparing the log-likelihood

To compare our method with (i) a correctly specified model taking into account the main effects of x_A and $\cos(z_1)$ as well as the interaction of x_A and $\cos(z_1)$ and (ii) a simple linear model including only the treatment x_A as a covariate, we drew 100 learning samples and 100 test samples using the data simulation procedure explained above and computed the out-of-sample log-likelihoods (i.e. based on the test data) for the models after applying them to each of the 100 learning data sets. The log-likelihood contributions

$$l\left((y, \mathbf{x})_i, \hat{\boldsymbol{\vartheta}}(\mathbf{z}_i)\right) = \left(y_i - \mathbf{x}_i^\top \hat{\boldsymbol{\vartheta}}(\mathbf{z}_i)\right)^2\tag{22}$$

with $\mathbf{x}_i = (1, x_{iA})^\top$ and $\hat{\boldsymbol{\vartheta}}(\mathbf{z}_i) = (\hat{\alpha}(\mathbf{z}_i), \hat{\beta}(\mathbf{z}_i))^\top$ are taken from the personalised models of our method (see Section 2.5). Note that for the simple linear model the log-likelihood contributions are defined as above, but only with constant parameters, for the fully specified model $\mathbf{x}_i = (1, x_A, \cos(z_1), x_A \cdot \cos(z_1))^\top$ and $\hat{\boldsymbol{\vartheta}} = (\hat{\alpha}, \hat{\beta}_A, \hat{\beta}_{\cos(z_1)}, \hat{\beta}_{A, \cos(z_1)})^\top$.

The log-likelihoods of our method are higher than the log-likelihoods of the simple and incorrect linear model and lower than the log-likelihoods of the correctly specified model (Figure 10). Therefore, we conclude that our method performs reasonably well.




Figure 10: Out-of-sample log-likelihoods obtained from the three models. Each line represents one simulated data set.

B.2. Dependence plots

For the same 100 simulated test data sets as above, we obtained the dependence plots. Figure 11 shows two dependence plots in which all 100 simulations are combined by layering them on top of each other. The dependence plot of partitioning variable z_1 (Figure 11a) shows a curve that is fairly similar to that of Figure 9, except that the effect is shrunken towards zero. Note that with a larger sample or differently tuned parameters (e.g. larger trees), one could get better results for the extreme treatment effects. As expected, for partitioning variables z_2 to z_{10} , there is only random fluctuation around zero (see as an example Figure 11b, which shows the dependence plot for z_2).

B.3. Variable importance

Variable importances for one simulated data set are shown in Figure 12. As expected, partitioning variable z_1 is the only variable with a clearly positive variable importance. Even though all partitioning variables are correlated, the method was able to distinguish between the correlation and predictive effect.

Affiliation:

Heidi Seibold

Institut für Epidemiologie, Biostatistik und Prävention, Abteilung Biostatistik

Universität Zürich

Hirschengraben 84, CH-8001 Zürich, Switzerland




Figure 11: Joint dependence plots of all 100 simulations.




Figure 12: Variable importances of the predictive factor z_1 and noise variables z_2 to z_{10} .

Achim Zeileis
Department of Statistics
Faculty of Economics and Statistics
University of Innsbruck
Universitätsstr. 15
A-6020 Innsbruck, Austria

Torsten Hothorn
Institut für Epidemiologie, Biostatistik und Prävention, Abteilung Biostatistik
Universität Zürich
Hirschengraben 84, CH-8001 Zürich, Switzerland
E-mail: Torsten.Hothorn@R-project.org
URL: <http://user.math.uzh.ch/hothorn/>